Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠.

Keller S, Yang M, Treadwell MJ, Hassell KL.

Health Qual Life Outcomes. 2017 Jun 2;15(1):117. doi: 10.1186/s12955-017-0661-5.

3.

Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery.

Dampier C, Jaeger B, Gross HE, Barry V, Edwards L, Lui Y, DeWalt DA, Reeve BB.

Pediatr Blood Cancer. 2016 Jun;63(6):1038-45. doi: 10.1002/pbc.25931. Epub 2016 Feb 8.

4.

Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.

Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26369. Epub 2016 Nov 28.

PMID:
27896936
5.

Breathlessness with pulmonary metastases: a multimodal approach.

Brant JM.

J Adv Pract Oncol. 2013 Nov;4(6):415-22. Review.

6.

Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease.

Dampier C, Barry V, Gross HE, Lui Y, Thornburg CD, DeWalt DA, Reeve BB.

Pediatr Blood Cancer. 2016 Jun;63(6):1031-7. doi: 10.1002/pbc.25944. Epub 2016 Feb 19.

7.

What is the evidence that hydroxyurea improves health-related quality of life in patients with sickle cell disease?

Darbari DS, Panepinto JA.

Hematology Am Soc Hematol Educ Program. 2012;2012:290-1. doi: 10.1182/asheducation-2012.1.290. Review.

PMID:
23233594
8.

Who rules the roost?

Zuckerman B, Sanoff MK, Augustyn M.

J Dev Behav Pediatr. 2010 Jan;31(1):72-4. doi: 10.1097/DBP.0b013e3181c8cc94.

PMID:
20081440
9.

Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl.

Zímová J, Zímová P.

Acta Dermatovenerol Croat. 2016 Jun;24(2):150-3.

PMID:
27477178
10.

Chronic hip pain in a boy with mental retardation and cerebral palsy.

Stein MT, Gottsegen D, Blasco PA, Wolraich M, Hennessy MJ.

J Dev Behav Pediatr. 2010 Apr;31(3 Suppl):S86-91. doi: 10.1097/DBP.0b013e3181d86e09.

PMID:
20414086
11.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
12.

Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.

Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI.

Health Qual Life Outcomes. 2017 Jul 5;15(1):136. doi: 10.1186/s12955-017-0713-x.

13.

Clinically meaningful interpretation of pediatric health-related quality of life in sickle cell disease.

Beverung LM, Varni JW, Panepinto JA.

J Pediatr Hematol Oncol. 2015 Mar;37(2):128-33. doi: 10.1097/MPH.0000000000000177.

14.

Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care.

Evensen CT, Treadwell MJ, Keller S, Levine R, Hassell KL, Werner EM, Smith WR.

Medicine (Baltimore). 2016 Aug;95(35):e4528. doi: 10.1097/MD.0000000000004528.

15.

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J.

JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. Review. Erratum in: JAMA. 2014 Nov 12;312(18):1932. JAMA. 2015 Feb 17;313(7):729.

PMID:
25203083
16.

Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.

Tsui BC, Davies D, Desai S, Malherbe S.

J Pediatr Hematol Oncol. 2004 Oct;26(10):678-80.

PMID:
15454842
17.

Home management of pain in sickle cell disease: a daily diary study in children and adolescents.

Dampier C, Ely E, Brodecki D, O'Neal P.

J Pediatr Hematol Oncol. 2002 Nov;24(8):643-7.

PMID:
12439036
18.

Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.

van Beers EJ, van Tuijn CF, Nieuwkerk PT, Friederich PW, Vranken JH, Biemond BJ.

Am J Hematol. 2007 Nov;82(11):955-60.

19.

Longitudinal evaluation of patient-reported outcomes measurement information systems measures in pediatric chronic pain.

Kashikar-Zuck S, Carle A, Barnett K, Goldschneider KR, Sherry DD, Mara CA, Cunningham N, Farrell J, Tress J, DeWitt EM.

Pain. 2016 Feb;157(2):339-47. doi: 10.1097/j.pain.0000000000000378.

20.

Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.

Krishnamoorthy P, Alyaarubi S, Abish S, Gale M, Albuquerque P, Jabado N.

Pediatrics. 2006 Aug;118(2):e537-9.

PMID:
16882790

Supplemental Content

Support Center